AR and prostate carcinoma: In prostate cancer, nelfinavir inhibits AR activation and nuclear translocation of SREBP-1 and ATF6 by regulating S2P-mediated intramembrane proteolysis, which is associated with ER stress, inhibition of unfolded protein response, apoptosis, and autophagy for treating castration-resistant prostate cancer (142).